News

ImmuneRegen, a wholly owned subsidiary of IR BioSciences Holdings, is collaborating with Hyperion Biotechnology to perform these tests at Hyperion’s research facility. Initial studies in a well-established mouse

Safety assessment confirmed PPL-100 to be safe and well tolerated at up to a 2400mg oral dose with only mild (grade 1 and 2) adverse events reported for

Clinical Data announced that over 150 patients have now been enrolled in the company’s phase III clinical study of vilazodone. The trial is being conducted as a double-blind,

Omr-IgG-am is a highly purified intravenous immunoglobulin (IVIG) solution that is currently marketed outside of the US. Under the terms of the agreement FFF has agreed to take

PharmaCare, a wholly-owned subsidiary of America’s largest retail pharmacy CVS Corporation, said it credits this significant shift to several factors, including the aggressive roll-out of the company’s patient-centric

Under the agreement, MaxCyte will optimize its proprietary cell loading system for the development of Medinet’s novel cancer immuno-cell therapy and implementation in a closed-system manufacturing process at

This license agreement allows MorphoSys to use the PER.C6 cell line in the production of clinical grade material for the development of its proprietary therapeutic antibody program MOR103.

Novartis said its application was based on a clinical development program containing data from more than 5,400 patients. The drug was accepted for US regulatory review in March

The move strengthens Kendle’s position in the clinical development industry, adding therapeutic expertise, diversifying its customer base and expanding its capacity to deliver large global trials. With the